XML 46 R31.htm IDEA: XBRL DOCUMENT v3.3.1.900

Collaborative Research, Development and License Agreements (Tables)

12 Months Ended

Dec. 31, 2015

Astra Zeneca

Summary of Revenue Recognized under Various Agreements

The following table summarizes the revenues earned under our agreement with AstraZeneca, included as collaboration revenue in our consolidated statements of operations (in thousands):

		Year ended December 31,
		2015				2014				2013
Initial payment		$	238			$	681			$	720
Subsequent payment			892				2,554				-
Performance of research activities			1,635				2,174				2,507
Total		$	2,765			$	5,409			$	3,227

Glaxo Smith Kline

Summary of Revenue Recognized under Various Agreements

The following table summarizes the revenues recognized under our agreement with GSK, included as collaboration revenue in our consolidated statements of operations (in thousands):

		Year ended December 31,
		2015				2014				2013
Initial payment		$	-			$	2,524			$	1,702
Total		$	-			$	2,524			$	1,702

National Institutes of Health

Summary of Revenue Recognized under Various Agreements

The following table summarizes the revenues recognized under the various arrangements with the NIH and NIAID, included as grant revenue in our consolidated statements of operations (in thousands):

		Year ended December 31,
		2015				2014				2013
NIAID contracts		$	-			$	2,095			$	4,103
All other NIH contracts			683				593				1,035
Total grant revenue		$	683			$	2,688			$	5,138

X

- Definition

Tabular disclosure of the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement. This item includes certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51671369&loc=d3e50766-111635

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 25
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=51671369&loc=SL6750900-111635

+ Details

Name:	us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_CounterpartyNameAxis=dvax_AstraZenecaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=dvax_GlaxoSmithKlineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=dvax_NationalInstitutesOfHealthMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: